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ABSTRACT 
Cannabis is a plant rich in various compounds that have a variety of impacts on the physiology of humans and the effects of these metabolites have a 
significant role in managing a variety of clinical diseases. A substantial increase in the use of SC (synthetic cannabinoids) had seen in the last few 
years especially infrequent cannabis users. The SCs will generate psychoactive effects that were similar to cannabis. However, the composition and 
pharmacological characteristics of these drugs make them possibly hazardous.  
Like all drugs, cannabis’ pharmacokinetics depends on the route of administration. Several studies showed that the bioavailability is less in oral 
administration when compared to inhalation. The main reason for this decrease in oral bioavailability is that cannabinoids undergo the first-pass 
metabolism before entering into the systemic circulation whereas in inhalation, it enters the circulation directly through the lungs. 
Cannabis sativa is a psychoactive plant that contains more than 500 components of which 104 cannabinoids had been identified. Of these, 2 
components such as Δ9-THC (Δ9-tetrahydrocannabinol) and CBD (cannabidol) were under the scientific investigation. Δ9-THC is the primary 
cannabinoid which was responsible for the consequences of psychotrophy. The potency of cannabis is assessed based on the THC concentration of a 
sample that is the main psychoactive cannabinoid in cannabis. The adverse effects are in direct relation to the concentration of THC in the product 
after regular cannabis use. It can be assumed that several cannabinoids will find their way into the pharmacies from preclinical research within a 
century. 
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INTRODUCTION 
Cannabis sativa (also called marijuana) is a psychoactive plant that 
contains more than 500 components of which 104 cannabinoids had 
been identified [1]. Of these, 2 components such as Δ9-THC and CBD 
were under scientific investigation to their pharmacological properties 
[1, 2]. Δ9-THC is the primary cannabinoid that was responsible for 
consequences of psychotrophy [3]. It interacts with and activates G 
protein-coupled CB1 and CB2 cannabinoid receptors [4]. 
In the 1930s and 40s the chemical structure of the first 
phytocannabinoids was determined effectively [3]. Another 
scientific discovery in the cannabinoid research was the 
identification of the particular cannabinoid receptors system in 
mammals and their cannabinoid endogenous ligands [1, 3]. 
The potency of cannabis is assessed based on the concentration of a 
sample that is the main psychoactive cannabinoid in cannabis. The 
adverse effects are in direct relation to the concentration of THC in 
the product after regular cannabis use [2]. 
Several studies over the last few years had shown that CBD levels may 
also have an important impact [5]. When compared to THC, it has a 
protective action against certain negative psychological effects and are 
also able to antagonize some of the undesired effects [2]. 
Various cannabis preparations are available on the illicit drug 
market and proper monitoring of those agents had helped scientists 
to evaluate the potency of products which is currently used [3]. 
Changes can then be compared with the prevalence of negative 
health consequences in users. Certain authors hypothesize that an 
increase in cannabis potency and in the ratio of the psychoactive 
component (Δ9-THC) to CBD might be the reason behind the 
increasing harmful effects associated with cannabis use [3]. 
Moreover, a substantial increase in the use of SCs had seen in the last 
few years especially infrequent cannabis users [1]. The SCs will 
generate psychoactive effects that were similar to cannabis and are 
also readily acquired through normal screenings that are 
undetected. However, the composition and pharmacological 
characteristics of these drugs make them possibly hazardous [5]. 
Cannabinoid receptors 
Two receptors of cannabinoids were recognized, The CB1 and the 
CB2 receptor had been identified as the 2 cannabinoid receptors and 
it exhibits 48% of the amino acid sequence [6]. 
In addition to their difference in amino acid sequence, they vary in 
signalling mechanisms, tissue distribution and sensitivity to certain 
agonists and antagonists showing marked selectivity for one or the 
other type of receptor [7]. Activation of cannabinoid receptors 
triggers adenylate cyclase inhibition, thus inhibiting the conversion 
of ATP to cyclic AMP [8]. 
CB1 receptors are widely expressed in basal ganglia, cerebellum, 
hippocampus and dorsal primary afferent spinal cord regions, 
reflecting the significance of the cannabinoid system in motor 
control, memory processing and pain modulation with low 
expression in the brain stem [7]. CB1 receptors are also found in 
endocrine glands, urinary and gastrointestinal tracts, spleen, 
leukocytes, heart and parts of the reproductive system [6]. 
CB2 receptors are seen primarily in immune cells, mainly in 
leukocytes, spleen and tonsils [9]. Immune cells also express CB1 
receptors, but in the immune system, there is significantly more 
mRNA for CB2 than CB1 receptors. Modulation of cytokine release is 
one of the main tasks of CB receptors in the immune system [6].  
CB1 receptor activation generates marijuana like impacts while CB2 
receptor activation does not [10]. Selective CB2 receptor agonists 
have therefore become an increasingly researched target for 
therapeutic uses of cannabinoids [11]. 
Known cannabinoids and their effects on cellular and system 
physiology 
In many tissues throughout the body, CB1 receptors are abundantly 
found in most of the brain areas and the peripheral nervous system 
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[5]. They are also found in some non-neuronal organs such as the 
liver, stomach, heart, testes and fat tissues [8]. Presynaptic 
activation of CB1 receptors in neuronal tissue inhibits the release of 
neurotransmitters such as gamma-Aminobutyric acid and glutamate 
by releasing βγ-subunits from the G protein complex, resulting in 
inhibition of voltage-gated calcium channels and vesicle release [12].  
While CB1 receptor activation typically inhibits the release of 
neuronal transmitters, in vivo activation of CB1 with Δ9-THC has been 
noted to occasionally boost the release of acetylcholine, dopamine 
and glutamate in different brain areas of rats [13].  
This is probably due to selective antagonism by Δ9-THC of 
endocannabinoids, as stated by Patel and Hillard [14] when anti-
anxiolytic effects of Δ9-THC administration in mice were observed. 
However, cannabidiol does not share psychotropic activity with Δ9-
THC, but acts as an inverse agonist or even antagonist of CB1 and 
thus attenuates in vivo response to Δ9-THC in various model species 
[15]. On the other side, cannabinoid CB2 receptors are more 
commonly found in immune related organs and attenuate pro-
inflammatory reactions such as cytokine release and immune cell 
response when it gets activated [16]. There is proof that CBD 
interacts as an inverse agonist with CB2 receptors resulting in a well-
documented decrease of clinical pro inflammatory markers such as 
TNF α, iNOS and COX-2 expression [17]. In relation to the impacts on 
CB2, CBD also interacts with receptors related to the immune system 
[18]. CB2 receptors are also found in reduced concentrations in both 
brain and peripheral neuronal tissue compared to CB1 receptors, but 
their function has not yet been elucidated [19].  
Pharmacokinetics of cannabis-based on route of administration 
Like all drugs, cannabis’ PK (pharmacokinetics) depends on the 
route of administration most of the human clinical trial have 
assessed the cannabis PK activity following inhalation or ingestion 
[20]. While various trials report a broad variety of PK parameters 
due to variations in dosage, it remains apparent that the onset, 
absorption rate and bioavailability of THC and CBD after inhalation 
are considerably greater than after ingestion or oral administration 
[21].
 
Table 1: Pharmacokinetics of cannabis based on route of administration 
Route of administration Inhalation Oral 
% Dose Consumed ~ 50% (loss due to pyrolysis) 100% 
Trajectory to Circulation Lungs–Bronchi-Bronchiole–Alveoli Stomach–Small Intestines–Portal Vein–Liver 
Other Factors Affecting Uptake Intake upon inhalation (puff duration, 
intake volume, holding time) 
Absorption (stomach contents, metabolic rate, genetic variants in CYP 
450 enzyme activity, enzyme regulation by other drugs) 
First-Pass Hepatic Metabolism Bypassed First-Pass Hepatic Metabolism by CYP450 enzymes 
Bioavailability 2–56% <20% 
Onset Immediate 30–90 min 
Time of Peak Plasma 5–10 min 1–6 h 
Duration 2-4 h 4–8 h 
 
THC can be detected in the blood almost instantly after smoking and 
maximum plasma levels can be measured after 5-10 min [22]. The 
reported peak values differ with the dose given. For example, one 
research revealed that cigarette inhalation comprising 1.75% THC 
(equal to 16 mg THC) and 3.55% THC (34 mg THC) resulted in mean 
plasma peak levels of 84.3 mg/ml and 162.2 mg/ml respectively 
[20]. However, the range of maximum plasma levels measured for 
the low dose cigarette was 50-129 mg/ml and the high dose 
cigarette was 76-267 mg. ml. 
When comparing reported bioavailability values such broad ranges 
are also discovered. In some research, the bioavailability of inhaled 
THC was recorded as 30%, 10-35%and 18% [23-25]. One research 
comparing THC’s pharmacokinetics between regular and occasional 
users found that bioavailability was 23-27% for regular users and 
10-14% for occasional users [26]. These variations arise from the 
difference in smoking techniques with variables such as puff length, 
quantity of intake and holding time to determine medication 
consumption [27].  
Fewer studies concentrated solely on CBD’s PK activity. One 
research revealed that the bioavailability of CBD after inhalation was 
31%, while others commented on the resemblance between THC and 
CBD in PK activity. It has been noted, however, that CBD may change 
THC’s PK activity and may mediate some of its adverse effects, such 
as paranoia and anxiety [28]. The precise reason for this modulatory 
impact is unknown, but the present scientific opinion is that CBD 
inhibits cytochrome P450 enzyme activity, which in turn affects THC 
metabolism especially after oral administration [29]. 
The main reason for this decrease in oral bioavailability is that 
cannabinoids undergo comprehensive first-pass metabolism with 
CYP 450 genes before systemic circulation is achieved [20]. 
With an inhalation, first-pass metabolism is prevented, as 
cannabinoids enter the circulation through the lungs [20]. 
Synthetic cannabinoids 
When scientists first explored the endocannabinoid system and tried to 
create new medicines for cancer pain, SCs appeared in the 1970s. SC 
emerged on the illegal drug market around the year 2000, where there 
prevalence was underestimated for a long time [30]. Since then their 
market place has risen steadily. The illicit market has recognized more 
than 560 synthetic psychoactive substances. In the last 5 y, there has 
been a steep increase with the appearance of 380 fresh synthetic drugs 
[31]. More than 160 SCs have been recognised in different products since 
2008. Most SCs are produced by Asian based chemical companies [32]. 
The rise in consumption of SCs was particularly remarkable 
compared to other new drugs on the market [33]. In general, these 
products are provided as herbal blends. Tablets, capsules or 
powders can also be purchased [34]. They are often smoked by pipe 
or as a joint [35]. Newer liquid formulations have recently emerged 
which can be vaporized by electronic cigarette [36]. 
The pharmacological characteristics of SCs are distinct from 
cannabis. This particular lipophilic [37] molecules are complete CB1 
(CBD receptor 1) and CB2 (CBD receptor 2) agonists. Their potential 
binding affinity to these receptors is also much greater than that of 
THC, resulting in significantly greater psychoactive effects [38].  
SC effects depend on the type of product used and its dose. Similarly, 
the pharmacokinetics depends on the administration route. In some 
cases the onset of psychoactive effects and physical symptoms 
begins a few minutes after smoking [39]. The effects are comparable 
to those observed after high doses of THC.  
Anxiety is frequently reported. Some users have described feeling 
limited in their movements, whereas no motor deficits are 
objectively observed. On average, the effects last for about 6 h, 
steadily decreasing until the next day [40-42]. 
Endocannabinoids 
Following the identification of cannabinoid receptors, endogenous 
ligands were detected for these receptors, called endocannabinoids, 
a family of eicosanoids [43]. There were 5 recognised 
endocannabinoids. These are N-arachidonylethanolamide 
(anandamide), 2-AG (2-arachidonylglycerol), 2-arachidonylglyceryl 
ether (noladin ether), O-arachidonyl-ethanolamine (virodhamine), 
and NADA (N-arachidonyl-dopamine) [44-47]. 
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Cannabinoid receptors and their endogenous ligands are the 
cannabinoid system found in mammals and many other species, 
which is teleologically millions of years old [48]. Endocannabinoids 
serve as neurotransmitters or neuromodulators [49]. Anandamide 
and NADA not only bind to cannabinoid receptors, but also activate 
VRI (vanilloid receptors) and selective ion channels associated with 
hyperalgesia [44, 50]. 
The endocannabinoids are produced on demand by cleavage of 
membrane lipid precursors and released in a stimulus dependent 
manner from cells [51]. They are quickly deactivated by absorption 
into cells and metabolized after its release [52, 53]. 
Therapeutic uses 
Many illness have been treated with cannabis preparations. In addition 
to phytocannabinoids, several synthetic cannabinoid derivatives and 
modulation of the endocannabinoid system are under clinical 
investigation that are devoid of psychotropic effects [54]. 
Therapeutic effects can be designed as: 1) clinically, established, 2) 
clinically relatively well-confirmed, 3) clinically less confirmed.  
Established effects 
Marinol (dronabinol, Δ9-THC) is approved for medical use in 
HIV/AIDS patients, with refractory nausea and vomiting induced by 
antineoplastic medicines used for cancer therapy and loss of 
appetite [55]. This impacts can be considered as established effects 
for THC and cannabis. THC is also efficient in ipecac syrup induced 
cancer cachexia and nausea. Cesamet (nabilone) is approved for 
cancer chemotherapy related nausea and vomiting [56]. 
Relatively well-confirmed effects 
In recent years there is also increasing evidence for therapeutic 
effects of THC and cannabis extracts in spasticity due to multiple 
sclerosis and spinal cord injury, chronic pain and Tourette‘s 
syndrome [57]. Effects in some other movement disorders 
(including dystonia and levodopa-induced dyskinesia), in asthma 
and glaucoma can also be regarded as relatively well-confirmed 
effects with small placebo controlled trials demonstrating benefits. 
However, results were sometimes conflicting [58]. 
Less confirmed effects 
There are several indications, in which mainly case reports suggest 
benefits [59]. These are allergies, inflammation, epilepsy, intractable 
hiccups, depression, bipolar disorders, anxiety disorders, addiction 
to opiates and alcohol, withdrawal symptoms, and disturbed 
behaviour in Alzheimer‘s disease [60]. 
Pharmacological effects of other cannabinoids 
CBD is a non-psychotropic cannabinoid that has been shown to have 
sedative, anti-epileptic, anti-dystonic, anti-emetic and anti-
inflammatory impacts. It decreases intraocular pressure, has been 
neuroprotective and has antagonised THC’s psychotropic and 
several other effects. In psychiatry, anxiolytic and anti-psychotic 
characteristics may be helpful [60]. 
Central nervous system and neurochemistry 
Cannabinoids interact with a multitude of neurotransmitters and 
neuromodulators, such as acetylcholine, dopamine, GABA (γ-
aminobutyric acid), histamine, serotonin, glutamate, 
norepinephrine, prostaglandins and opioid peptides [42]. 
Cannabinoids influence the activity of most neurotransmitters in a 
complex manner, which sometimes may result in contradictory 
effects with suppression or induction/intensification of seizures, 
emesis, pain and tremor depending on subject and condition [42]. 
Circulatory system 
THC may be lead to tachycardia [61] and increase cardiac output 
with enhanced cardiac labour and demand for oxygen [62]. It can 
also produce peripheral vasodilation and orthostatic hypotension. 
Tachycardia by THC may easily be explained by vagal inhibition [63]. 
Regular use can lead to bradycardia [64].  
Some other organ systems and effects 
Bone formation 
Preliminary observations show that endocannabinoids seem to 
stimulate bone formation [65]. 
Cancer 
Cannabinoid agonists inhibited in vitro the proliferation of human 
breast cancer cells, and directly applied at the tumour site, showed 
antineoplastic activity against malignant gliomas [66, 67]. 
Digestive tract 
Cannabinoid agonists inhibit gastrointestinal motility and gastric 
emptying in rats [68]. THC has induced a substantial delay in gastric 
emptying in a research with humans [69]. Furthermore, CB agonists 
inhibited rat’s secretion of gastric acid induced by pentagastrin [70]. 
Eye 
The proof of cannabinoid receptors at various locations (anterior eye, 
retina and corneal epithelium) indicates that cannabinoids regulates 
various physiological functions in the human eye [71]. Vasodilation in 
the eye is noted after expose to THC as a conjunctival reddening. THC 
and some other cannabinoids reduce intraocular pressure [71]. CB1 
receptors in the eye are involved in this effect while intraocular 
pressure is not reduced by CB2 receptor agonists [72].  
Toxicity 
There was no substantiation of acute deadly instances in humans. 
However, THC can trigger myocardial infarction owing to circulation 
impacts [33, 34]. This is unlikely to occur in healthy individuals, but 
in people with heart disease who may at danger for orthostatic 
hypotension or elevated heart rate. 
It is controversial whether heavy periodic consumption can lead to 
long term cognition impairment [35-37]. But irreversible impairment 
appears to be minimal if it occurs. Early users who begin their use 
before the age of 17 had poorer cognitive performance, particularly 
verbal IQ compared to users who begin later or non-users [38].  
There is conflicting evidence that infants exposed to THC in utero 
suffer from developmental and cognitive impairment [39]. In 
vulnerable people, marijuana can induce schizophrenic psychosis 
and there is increasing evidence that there is a distinct cannabis 
psychosis. 
Tolerance and dependence 
Tolerance develops to most of the effects of THC causing changes in 
endocannabinoid formation and brain content [73, 59]. Cannabinoid 
use has been shown to replace increased heart rate to normal or 
slow heart rate and it also results in orthostatic hypotension [55, 
60]. Tolerance can be linked primarily to modify the 
pharmacodynamics, probably based on receptor down regulation 
and desensitization of the receptor [74]. 
After abrupt cessation of chronic dosing with elevated doses of THC, 
withdrawal was noted in humans [75]. Subjects complaint of 
internal disturbances, irritability, insomnia and reported hot flashes, 
sweating, rhinorrhoea, loose stools, hiccups and anorexia [76]. 
Symptoms of withdrawal are generally mild in humans and the risk 
of physical and psychological dependence is small compared to 
opiates, tobacco, alcohol and benzodiazepines [56-58]. 
CONCLUSION 
Cannabis is a plant rich in various compounds that has a variety of 
impacts on the physiology of humans. These impacts are described 
mainly to cannabinoids and terpenes, large metabolite families that 
can interact with many of the body’s cellular and physiological 
processes. While much studies are still remains to be done, the 
effects of these metabolites are a significant tool for managing a 
variety of clinical diseases.  
Various concentrations of these compounds have distinct 
physiological impact and may affect the clinical utility based on how 
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the plant is given to patients. It can be assumed that several 
cannabinoids and cannabinoid system modulations will find their 
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